Marla Shapiro, MDCM, explains how OPTION-VMS actigraphy data corroborated patient-reported sleep improvements with fezolinetant (Veozah) as early as week 4.
|Articles|August 4, 2011
Hormone Replacement Therapy (HRT) Evidence-based Guidelines
Author(s)Mahdy El-Mazzahy, MD
Discover effective strategies and insights to navigate menopause, enhancing well-being and embracing this transformative life stage.
Advertisement
Advertisement
Related to this article
Soma Mandal, MD, is launching “Mind, Body, & the Pause: the Perimenopause and Beyond Series” on Contemporary OB/GYN, featuring specialists from across Hackensack Meridian Health.
Wen Shen, MD, describes perimenopause as an opportunity for clinicians to revisit pregnancy-related risk factors and address cardiovascular health proactively.
A recap of the top videos and podcasts from Contemporary OB/GYN in September 2026, featuring expert interviews on salpingectomy, testosterone evidence, and more.
A recap of the top headlines from Contemporary OB/GYN in September 2026, spanning ACOG's respiratory vaccine guidance to the launch of the Missed & Dismissed podcast.
A recap of Contemporary OB/GYN's top FDA and regulatory news from September 2026.
Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.
Wen Shen, MD, highlights perimenopause as an important period for identifying health risks and supporting healthy aging beyond the menopausal transition.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Low birth volume and unprofitability associated with obstetric services losses
2
Ultrasound findings after medication management of early pregnancy loss
3
Soma Mandal, MD, to launch 'Mind, Body, & the Pause' perimenopause podcast on Contemporary OB/GYN
4
IMS: Fezolinetant's improvements in sleep quality, hot flashes as early as week 4
5